Cited by 752Bone health and osteoporosis researchMenopause: Health Impacts and TreatmentsBone health and treatments

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

Cummings, Steven R., Karpf, David B., Harris, Fran, Genant, Harry K., Ensrud, Kristine, LaCroix, Andrea Z., Black, Dennis M.·2002·The American Journal of Medicine

DOI 10.1016/s0002-9343(01)01124-x

Open this paper in CoChat — free account

Abstract

Purpose To estimate how much the improvement in bone mass accounts for the reduction in risk of vertebral fracture that has been observed in randomized trials of antiresorptive treatments for osteoporosis.Methods After a systematic search, we conducted a meta-analysis of 12 trials to describe the relation between improvement in spine bone mineral density and reduction in risk of vertebral fracture in postmenopausal women. We also used logistic models to estimate the proportion of the reduction in risk of vertebral fracture observed with alendronate in the Fracture Intervention Trial that was due to improvement in bone mineral density.Results Across the 12 trials, a 1% improvement in spine bone mineral density was associated with a 0.03 decrease (95% confidence interval [CI]: 0.02 to 0.05) in the relative risk (RR) of vertebral fracture. The reductions in risk were greater than predicted from improvement in bone mineral density; for example, the model estimated that treatments predicted to reduce fracture risk by 20% (RR = 0.80), based on improvement in bone mineral density, actually reduce the risk of fracture by about 45% (RR = 0.55). In the Fracture Intervention Trial, improvement in spine bone mineral density explained 16% (95% CI: 11% to 27%) of the reduction in the risk of vertebral fracture with alendronate.Conclusion Improvement in spine bone mineral density during treatment with antiresorptive drugs accounts for a predictable but small part of the observed reduction in the risk of vertebral fracture.

Integrity signals

Registry

Crossref · 10.1016/s0002-9343(01)01124-x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citation
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>
Ettinger, B. (1999) · JAMA · doi:10.1001/jama.282.7.637 · Cited by 3,366
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citation
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citation
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Self-citation
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M. C., Marcelli, C., Grandjean, H., Müller, C., Cormier, C., Bréart, G., Meunier, P. J., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 984
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citation

Show all 35 references

Research works printed but not linked: 4

Cummings, 1996, Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs, J Bone Miner Res, 11, S102
Genant, 1998, Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis, Bone, 23, S175
Black, 1993, Prediction of new vertebral deformities, J Bone Miner Res, 8, S135
Cann, 1999, PTH effects in the femur, J Bone Miner Res, 14, S137

Sorted by citations

Items 101–200 of 751

Biomechanical computed tomography—noninvasive bone strength analysis using clinical computed tomography scans
Keaveny, T. M. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05348.x · Cited by 128
Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study
McCloskey, E. V., Selby, P. L., Davies, M., Robinson, J., Francis, R. M., Adams, J. E., Kayan, K., Beneton, M. N. C., Jalava, T., Pylkkänen, L. H., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040116 · Cited by 128
Bone mass and architecture determination: state of the art
Griffith, J. F., & Genant, H. K. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.003 · Cited by 126
Self-citation
Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study
Adami, S., Isaia, G., Luisetto, G., Minisola, S., SINIGAGLIA, L., Gentilella, R., Agnusdei, D., Iori, N., & Nuti, R. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060715 · Cited by 125
Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate
Bruyère, O., Roux, C., Detilleux, J., Slosman, D. O., Spector, T. D., Fardellone, P., Brixen, K., Devogelaer, J., Díaz Curiel, M., Albanese, C. V., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2758 · Cited by 125
Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status
Langdahl, B. L., Marín, F., Shane, E. J., Dobnig, H., Zanchetta, J., Maricic, M. J., Krohn, K., See, K., & Warner, M. R. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0917-y · Cited by 126
Bisphosphonates: how do they work?
Papapoulos, S. E. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.001 · Cited by 133
Aromatase Inhibitors and Bone Health in Women With Breast Cancer
Chien, A. J., & Goss, P. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5382 · Cited by 126
Effects of 3- and 5-Year Treatment With Risedronate on Bone Mineralization Density Distribution in Triple Biopsies of the Iliac Crest in Postmenopausal Women
Zoehrer, R., Roschger, P., Paschalis, E. P., Hofstaetter, J. G., Durchschlag, E., Fratzl, P., Phipps, R. J., & Klaus Klaushofer, A. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060401 · Cited by 121
Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
Seeman, E. (2007) · Bone · doi:10.1016/j.bone.2007.06.010 · Cited by 123
Role of Trabecular Microarchitecture in Whole-Vertebral Body Biomechanical Behavior
Fields, A. J., Eswaran, S. K., Jekir, M. G., & Keaveny, T. M. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090317 · Cited by 121
Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis
Delmas, P. D., Munoz, F., Black, D. M., Cosman, F., Boonen, S., Watts, N. B., Kendler, D. L., Eriksen, E. F., Mesenbrink, P. G., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090310 · Cited by 122
Self-citation
Pathogenesis of osteoporosis
Raisz, L. G., & Rodan, G. A. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00055-5 · Cited by 122
Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
Belaya, Z. E., Belova, K. Y., Biryukova, E. V., Dedov, I. I., Dzeranova, L. K., Drapkina, O. M., Dreval', A. V., Dubovitskaya, Т. A., Dudinskaya, Е. N., Ershova, O. B., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12930 · Cited by 138
Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta-Analyses
Delmas, P. D., Li, Z., & Cooper, C. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301228 · Cited by 118
Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate
Seibel, M. J., Naganathan, V., Barton, I. P., & Grauer, A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301231 · Cited by 115
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
Reginster, J., Sarkar, S., Zegels, B., Henrotin, Y. E., Bruyère, O., Agnusdei, D., & Collette, J. (2003) · Bone · doi:10.1016/j.bone.2003.10.004 · Cited by 115
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective
Boonen, S., Ferrari, S., Miller, P. D., Eriksen, E. F., Sambrook, P. N., Compston, J. E., Reid, I. R., Vanderschueren, D., & Cosman, F. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1570 · Cited by 114
Risedronate Prevents New Vertebral Fractures in Postmenopausal Women at High Risk
Watts, N. B., Josse, R. G., Hamdy, R. C., Hughes, R., Manhart, M. D., Barton, I. P., Calligeros, D., & Felsenberg, D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020400 · Cited by 112
In Vitro, Ex Vivo , and In Vivo Methodological Approaches for Studying Therapeutic Targets of Osteoporosis and Degenerative Joint Diseases: How Biomarkers Can Assist?
Schaller, S., Henriksen, K., Høegh-Andersen, P., Søndergaard, B. C., Sumer, E. U., Tankó, L. B., Qvist, P., & Karsdal, M. A. (2005) · Assay and Drug Development Technologies · doi:10.1089/adt.2005.3.553 · Cited by 113
A Biomechanical Analysis of the Effects of Resorption Cavities on Cancellous Bone Strength
Hernandez, C. J., Gupta, A. K., & Keaveny, T. M. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060514 · Cited by 111
Important Determinants of Bone Strength
Friedman, A. (2006) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000208612.33819.8c · Cited by 111
Exercise and Bone Mineral Density in Premenopausal Women: A Meta-Analysis of Randomized Controlled Trials
Kelley, G. A., Kelley, K. S., & Kohrt, W. M. (2013) · International Journal of Endocrinology · doi:10.1155/2013/741639 · Cited by 120
Progressive High-Intensity Resistance Training and Bone Mineral Density Changes Among Premenopausal Women
James, M. M.-S., & Carroll, S. (2006) · Sports Medicine · doi:10.2165/00007256-200636080-00005 · Cited by 75
Raloxifene enhances vertebral mechanical properties independent of bone density
Allen, M. R., Iwata, K., Sato, M., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.05.007 · Cited by 109
Devastation of adult stem cell pools by irradiation precedes collapse of trabecular bone quality and quantity
Green, D. E., Adler, B. J., Chan, M. E., & Rubin, C. T. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1505 · Cited by 107
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data
Bell, K., Hayen, A. D., Macaskill, P., Irwig, L., Craig, J. C., Ensrud, K. E., & Bauer, D. C. (2009) · BMJ · doi:10.1136/bmj.b2266 · Cited by 109
Self-citation
Emerging concepts in osteoporosis and bone strength
Rubin, C. D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x50525 · Cited by 106
Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability in Clinical Traumatology Practice
Rey, J. R. C., Vaquero-Cervino, E., Rentero, M. L., Crespo, E. C., Oteo‐Álvaro, Á., & Casillas, M. (2009) · The Open Orthopaedics Journal · doi:10.2174/1874325000903010014 · Cited by 108
Improvements in Vertebral Body Strength Under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results From the EUROFORS Study
Graeff, C., Chevalier, Y., Charlebois, M., Varga, P., Pahr, D. H., Nickélsen, T., Morlock, M. M., Glüer, C., & Zysset, P. K. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090416 · Cited by 105
Compressive axial mechanical properties of rat bone as functions of bone volume fraction, apparent density and micro-ct based mineral density
Cory, E., Nazarian, A., Entezari, V., Vartanians, V. M., Müller, R., & Snyder, B. D. (2009) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2009.10.047 · Cited by 104
The effects of calcitriol on falls and fractures and physical performance tests
Gallagher, J. C. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.03.059 · Cited by 103
Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method
Imai, K., Ohnishi, I., MATSUMOTΟ, T., Yamamoto, S., & Nakamura, K. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0750-8 · Cited by 108
New advances in imaging osteoporosis and its complications
Griffith, J. F., & Genant, H. K. (2012) · Endocrine · doi:10.1007/s12020-012-9691-2 · Cited by 100
Self-citation
Bisphosphonate treatment of osteoporosis
Watts, N. B. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00069-1 · Cited by 100
The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: A comparative review
Herrmann, M., & Seibel, M. J. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.03.020 · Cited by 98
Skeletal Heterogeneity and the Purposes of Bone Remodeling
PARFITT, A. M. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50016-7 · Cited by 98
Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis.
Seibel, M. J. (2006) · PubMed Central · Cited by 97
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
Chesnut, C. H., Ettinger, M. P., Miller, P. D., Baylink, D. J., Emkey, R. D., Harris, S. T., Wasnich, R. D., Watts, N. B., Schimmer, R. C., & Recker, R. R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x30752 · Cited by 98
Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis
Vasikaran, S. D. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360801949442 · Cited by 97
Efficacy and safety of ibandronate given by intravenous injection once every 3 months
Adámi, S., Felsenberg, D., Christiansen, C., Robinson, J., Lorenc, R. S., Mahoney, P., Coutant, K., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.007 · Cited by 99
11β-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone
Cooper, M. S., Blumsohn, A., Goddard, P. E., Bartlett, W. A., Shackleton, C. H. L., Eastell, R., Hewison, M., & Stewart, P. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-022025 · Cited by 97
Nonresponders to Osteoporosis Therapy
Lewiecki, E. M. (2003) · Journal of Clinical Densitometry · doi:10.1385/jcd:6:4:307 · Cited by 96
Epidemiology of Vertebral Fractures: Implications for Vertebral Augmentation
Melton, L. J., & Kallmes, D. F. (2006) · Academic Radiology · doi:10.1016/j.acra.2006.01.005 · Cited by 97
Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility.
McCormick, R. K. (2007) · PubMed · Cited by 94
Densitometric, morphometric and mechanical distributions in the human proximal femur
Nazarian, A., Muller, J. A., Zurakowski, D., Müller, R., & Snyder, B. D. (2007) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2006.11.022 · Cited by 92
Diseases Affecting Bone Quality: Beyond Osteoporosis
Unnanuntana, A., Rebolledo, B. J., Khair, M. M., DiCarlo, E. F., & Lane, J. M. (2010) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-010-1694-9 · Cited by 97
Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: A one-year prospective controlled study using high-resolution peripheral quantitative computed tomography
Hansen, S. G., Hauge, E., Rasmussen, L. M., Jensen, J. B., & Brixen, K. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1540 · Cited by 92
Bone density vs bone quality: What’s a clinician to do?
Licata, A. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.08041 · Cited by 91
Association between dietary intake of flavonoid and bone mineral density in middle aged and elderly Chinese women and men
Zhang, Z.-Q., He, L.-P., Liu, Y., Liu, J., Su, Y.-X., & Chen, Y. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2763-9 · Cited by 90
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study
Hosking, D. J., Adami, S., Felsenberg, D., Cannata-Andía, J. B., Välimäki, M. J., Benhamou, L., Reginster, J., Yacik, C., Rybak-Feiglin, A., Petruschke, R. A., et al. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002009 · Cited by 87
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density
Genant, H. K., Engelke, K., Hanley, D. A., Brown, J. P., Omizo, M., Bone, H. G., Kivitz, A., Fuerst, T. P., Wang, H., Austin, M., et al. (2010) · Bone · doi:10.1016/j.bone.2010.04.594 · Cited by 89
Self-citation
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Franchimont, N., Putzeys, V., Collette, J., Vermeire, S., Rutgeerts, P., Vos, M. D., Gossum, A. V., Franchimont, D. P., Fiasse, R., Pelckmans, P. A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02152.x · Cited by 87
Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis
Mellibovsky, L., Prieto‐Alhambra, D., Mellibovsky, F., Güerri‐Fernández, R., Nogués, X., Randall, C. J., Hansma, P. K., & Díez‐Pérez, A. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2497 · Cited by 86
Mechanisms of osteoporosis therapy: A bone strength perspective
Bouxsein, M. (2003) · Clinical cornerstone · doi:10.1016/s1098-3597(03)90043-3 · Cited by 85
Calcium and Vitamin D in Sarcoidosis: How to Assess and Manage
Burke, R. R., Rybicki, B. A., & Rao, D. (2010) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0030-1262215 · Cited by 86
Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis
Adámi, S., Martin, J. S., Muñoz‐Torres, M., Econs, M. J., Xie, L., Dalsky, G. P., McClung, M. R., Felsenberg, D., Brown, J. P., Brandi, M. L., et al. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0485-y · Cited by 84
Clinical use of serum and urine bone markers in the management of osteoporosis
Srivastava, A. K., Vliet, E. L., Lewiecki, E. M., Maricic, M. J., Abdelmalek, A., Gluck, O. S., & Baylink, D. J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x49635 · Cited by 84
Effects of Milk and Dairy Products on the Prevention of Osteoporosis and Osteoporotic Fractures in Europeans and Non-Hispanic Whites from North America: A Systematic Review and Updated Meta-Analysis
Matía‐Martín, P., Torrego-Ellacuría, M., Larrad-Sáinz, A., Fernández, C., Triana, F. M. C., & Rubio, M. Á. (2018) · Advances in Nutrition · doi:10.1093/advances/nmy097 · Cited by 83
Comparison of BMD precision for Prodigy and Delphi spine and femur scans
Shepherd, J., Fan, B., Lu, Y., Lewiecki, E. M., Miller, P. D., & Genant, H. K. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0127-9 · Cited by 83
Self-citation
Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
Boonen, S., Body, J., Boutsen, Y., Devogelaer, J., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1812-1 · Cited by 83
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study
Kang, J., Keller, J. J., & Lin, H. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2213-5 · Cited by 82
Microstructure and nanomechanical properties in osteons relate to tissue and animal age
Koltsov, J. C. B., Gourion‐Arsiquaud, S., Havill, L. M., Baker, S. P., Boskey, A. L., & van der Meulen, M. C. H. (2010) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2010.10.018 · Cited by 82
Ultrasonic bone assessment: “The time has come”
Siffert, R. S., & Kaufman, J. J. (2006) · Bone · doi:10.1016/j.bone.2006.07.018 · Cited by 80
How can bone turnover modify bone strength independent of bone mass?
Hernandez, C. J. (2008) · Bone · doi:10.1016/j.bone.2008.02.001 · Cited by 79
Increases in BMD Correlate With Improvements in Bone Microarchitecture With Teriparatide Treatment in Postmenopausal Women With Osteoporosis
Chen, P., Miller, P. D., Recker, R. R., Resch, H., Rana, A. E., Pavo, I. J., & Sipos, A. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070413 · Cited by 79
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density
Bonnick, S. L., Broy, S. B., Kaiser, F. E., Teutsch, C., Rosenberg, E., DeLucca, P. T., & Melton, M. E. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188035 · Cited by 79
Monitoring in vivo (re)modeling: A computational approach using 4D microCT data to quantify bone surface movements
Birkhold, A., Razi, H., Weinkamer, R., Duda, G. N., Checa, S., & Willie, B. M. (2015) · Bone · doi:10.1016/j.bone.2015.02.027 · Cited by 85
Uses and limitations of bone mineral density measurements in the management of osteoporosis.
Small, R. E. (2005) · PubMed Central · Cited by 79
Effect of Hormone Replacement, Alendronate, or Combination Therapy on Hip Structural Geometry: A 3-Year, Double-Blind, Placebo-Controlled Clinical Trial
Greenspan, S. L., Beck, T., Resnick, N. M., Bhattacharya, R. K., & Parker, R. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050508 · Cited by 79
Mineralization, microdamage, and matrix: How bisphosphonates influence material properties of bone
Allen, M. R., & Burr, D. B. (2007) · BoneKEy-Osteovision · doi:10.1138/20060248 · Cited by 78
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial
Lems, W. F., Lodder, M. C., Lips, P. T. A. M., Bijlsma, J. W. J., Geusens, P., Schrameijer, N., van de Ven, C. M., & Dijkmans, B. A. C. (2006) · Osteoporosis International · doi:10.1007/s00198-005-0037-2 · Cited by 76
Dissociation Between Global Markers of Bone Formation and Direct Measurement of Spinal Bone Formation in Osteoporosis
Frost, M. L., Fogelman, I., Blake, G. M., Marsden, P. K., & Cook, G. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040818 · Cited by 76
Effects of osteoporosis medications on bone quality
Benhamou, C.-L. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.06.004 · Cited by 78
Calcitonin ??? A Drug of the Past or for the Future?
Karsdal, M. A., Henriksen, K., Arnold, M., & Christiansen, C. (2008) · BioDrugs · doi:10.2165/00063030-200822030-00001 · Cited by 77
How useful are measures of BMD and bone turnover?
Miller, P. D., Hochberg, M. C., Wehren, L. E., Ross, P. D., & Wasnich, R. D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x41390 · Cited by 74
Bone Densitometry and Vertebral Fracture Assessment
Lewiecki, E. M. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0018-z · Cited by 76
Treat-to-target for Osteoporosis: Is Now the Time?
Lewiecki, E. M., Cummings, S. R., & Cosman, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3680 · Cited by 74
Self-citation
Monitoring of Dual-Energy X-ray Absorptiometry Measurement in Clinical Practice
Maghraoui, A. E., Achemlal, L., & Bezza, A. (2006) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2006.03.014 · Cited by 70
Newer Perspectives on Calcium Nutrition and Bone Quality
Heaney, R. P., & Weaver, C. M. (2005) · Journal of the American College of Nutrition · doi:10.1080/07315724.2005.10719506 · Cited by 72
The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients—a randomized trial
Rief, H., Petersen, L. C., Omlor, G., Akbar, M., Bruckner, T., Rieken, S., Haefner, M. F., Schlampp, I., Förster, R., Debus, J., et al. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.06.008 · Cited by 71
Summary of AHRQ’s Comparative Effectiveness Review of Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis: Update of the 2007 Report
Levis, S., & Theodore, G. H. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s4-b.1 · Cited by 71
Theoretical Implications of the Biomechanical Fracture Threshold
Keaveny, T. M., & Bouxsein, M. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080406 · Cited by 71
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies
Byrjalsen, I., Leeming, D. J., Qvist, P., Christiansen, C., & Karsdal, M. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0462-5 · Cited by 72
Bisphosphonates
McClung, M. R. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00079-8 · Cited by 72
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength
Randall, C. J., Bridges, D. C., Güerri‐Fernández, R., Nogués, X., Puig, L., del Pliego, E. T., Mellibovsky, L., Hoffseth, K., Stalbaum, T., Srikanth, A., et al. (2013) · Journal of Medical Devices · doi:10.1115/1.4024829 · Cited by 69
Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction
Miller, P. D. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0018-6 · Cited by 69
Looking beyond bone mineral density
Griffith, J. F., Engelke, K., & Genant, H. K. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05378.x · Cited by 69
Self-citation
Is bone quality associated with collagen age?
Leeming, D. J., Henriksen, K., Byrjalsen, I., Qvist, P., Madsen, S. H., Garnero, P., & Karsdal, M. A. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0904-3 · Cited by 71
Age-specific profiles of tissue-level composition and mechanical properties in murine cortical bone
Raghavan, M., Sahar, N. D., Kohn, D. H., & Morris, M. D. (2012) · Bone · doi:10.1016/j.bone.2011.12.026 · Cited by 73
High risk of osteoporosis in male patients with eating disorders
Mehler, P. S., Sabel, A. L., Watson, T., & Andersen, A. E. (2008) · International Journal of Eating Disorders · doi:10.1002/eat.20554 · Cited by 67
Bone microarchitecture and strength
Dempster, D. W. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1474-4 · Cited by 66
Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective
Bouxsein, M., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080301 · Cited by 67
Osteoporosis and inflammatory bowel disease
Bernstein, C. N., & Leslie, W. D. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01876.x · Cited by 65
Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies
Bonura, F. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2021 · Cited by 66
The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy
Epstein, S. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.3.379 · Cited by 65
Monitoring osteoporosis treatment
Compston, J. E. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.09.007 · Cited by 64
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial
Palomba, S., Orio, F., Russo, T., Falbo, A. I., Tolino, A., Manguso, F., Nunziata, V., Mastrantonio, P., Lombardi, G., & Zullo, F. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1800-5 · Cited by 64
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass
Recker, R. R., Kendler, D. L., Recknor, C. P., Rooney, T. W., Lewiecki, E. M., Utian, W. H., Cauley, J. A., Lorraine, J., Qu, Y., Kulkarni, P. M., et al. (2006) · Bone · doi:10.1016/j.bone.2006.11.001 · Cited by 65
Goal-directed treatment of osteoporosis
Cummings, S. R., Cosman, F., Eastell, R., Reid, I. R., Mehta, M., & Lewiecki, E. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1854 · Cited by 62
Self-citation

Authors: Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M.
Affiliations: University of California, San Francisco (US)
Geron (United States) (US)
University of Minnesota (US)
University of Washington (US)
Corresponding author: Cummings, Steven R.
ORCID: Cummings, Steven R.
Genant, Harry K.
Ensrud, Kristine
LaCroix, Andrea Z.
Black, Dennis M.
Venue: The American Journal of Medicine
Publisher: Elsevier BV
Published: 2002-03
Volume: 112
Issue: 4
Pages: 281-289
ISSN: 0002-9343 (ISSN-L)
DOI: 10.1016/s0002-9343(01)01124-x
OpenAlex: W2110828193
Cited by: 752
References: 35
Citations by year: 2026: 7 · 2025: 10 · 2024: 17 · 2023: 12 · 2022: 12 · 2021: 16 · 2020: 25 · 2019: 10 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 19 · 2014: 24 · 2013: 29 · 2012: 43
FWCI: 8.42
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The American Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: osteoporosis, vertebral fractures, bone mineral density, antiresorptive agents, alendronate, postmenopausal women, Fracture Intervention Trial, fracture risk reduction, bone mass
MeSH terms: Bone Resorption, Female, Fractures, Spontaneous, Humans, Regression Analysis, Risk Factors, Spine, Bone Density, Osteoporosis, Postmenopausal, Logistic Models, Spinal Fractures, Alendronate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks